Michael Burns, Clinical Development Senior Medical Director at Pfizer, shared on LinkedIn:
“New clinical data in mCRC published. Congrats to the investigators and team.
Randomized Phase 1 of telisotuzumab adizutecan (ABBV-400) in combination with Bev versus Lonsurf/Bev now out in Annals of Oncology.
This project was one I’m proud to have been a part of, and glad to see the final publication.
Key Highlights: Mechanism of Action: Evaluates a novel c-Met-directed antibody-drug conjugate (ADC) combined with anti-VEGF therapy.
Study Design: Provides randomized Phase 1 clinical data exploring efficacy and tolerability profiles in heavily pretreated patient populations.
Thanks to all the investigators, study teams, and patients and families who contributed to this. Phase 3 ongoing!”
Read the full manuscript.
Title: A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer
Authors: M. Cecchini, M. Cruz-Correa, S-W. Han, K. Raghav, A. Landa-Magdalena, J.H. Strickler, A. Calvo, A. Hollebecque, T.E. Nakajima, G. Perl, V. Jain, Z. Hunter, E.M. Chan, M. Blaney, R. Li, A. Vasilopoulos, A. Parikh, M.R. Sharma.
You may also be interested in: Temab-A + Bevacizumab at ESMO 2026: Long-Term Phase I Results in Previously Treated Colorectal Cancer
